PL02.03 Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK+ NSCLC: First Report of a Phase 3 Trial (ALTA-1L)

Authors :: Scott N. Gettinger
J. Haney
M.R. Garcia Campelo
J-S. Lee
R. Camidge
K.H. Lee
Hwa Ryeon Kim
Cesare Gridelli
G-C. Chang
Alexander I. Spira
M-J. Ahn
M. Tiseo
Enriqueta Felip
Maximilian Hochmair
Raffaele Califano
S. Ghosh
Alessandra Bearz
J.Y. Li
Frank Griesinger
Dong Wook Kim
J.C.-H. Yang
David Kerstein
Alessandro Morabito
Sanjay Popat
J-Y. Han
Angelo Delmonte
Source :: Journal of Thoracic Oncology. 13:S184-S185
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Subjects :: Pulmonary and Respiratory Medicine
ALK inhibitor
Oncology
Brigatinib
Crizotinib
business.industry
medicine.drug_class
Cancer research
medicine
In patient
business
medicine.drug

Tools